Literature DB >> 31843065

PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.

Hojjat Ahmadzadehfar1, Kambiz Rahbar2, Markus Essler3, Hans Jürgen Biersack3.   

Abstract

To date, several papers have been published about prostate-specific membrane antigen (PSMA)-based radioligand diagnostic and therapeutic approaches. This paper mainly provides information for nuclear medicine physicians that are clinically engaged in the diagnosis and treatment of prostate cancer patients. It aims to present the utility of PSMA imaging and therapy in a step-by-step practical approach; thus, it does not discuss radiochemistry and the molecular basics of PSMA.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31843065     DOI： 10.1053/j.semnuclmed.2019.07.003

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN： 0001-2998            Impact factor:   4.446


  7 in total

1.  Utility of PSMA-PET imaging.

Authors:  Hojjat Ahmadzadehfar; Hans Jürgen Biersack
Journal:  Dtsch Arztebl Int       Date:  2021-09-06       Impact factor: 5.594

Review 2.  Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology.

Authors:  Martha Sahylí Ortega Pijeira; Herlys Viltres; Jan Kozempel; Michal Sakmár; Martin Vlk; Derya İlem-Özdemir; Meliha Ekinci; Seshasai Srinivasan; Amin Reza Rajabzadeh; Eduardo Ricci-Junior; Luciana Magalhães Rebelo Alencar; Mohammed Al Qahtani; Ralph Santos-Oliveira
Journal:  EJNMMI Radiopharm Chem       Date:  2022-04-25

3.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

Review 4.  Recent updates and developments in PET imaging of prostate cancer.

Authors:  Steven P Rowe; Geoffrey B Johnson; Martin G Pomper; Michael A Gorin; Spencer C Behr
Journal:  Abdom Radiol (NY)       Date:  2020-12

Review 5.  The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer.

Authors:  Alex J Poot; Marnix G E H Lam; Max M van Noesel
Journal:  Front Oncol       Date:  2020-11-19       Impact factor: 6.244

6.  Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).

Authors:  Hojjat Ahmadzadehfar; Kambiz Rahbar; Richard P Baum; Robert Seifert; Katharina Kessel; Martin Bögemann; Harshad R Kulkarni; Jingjing Zhang; Carolin Gerke; Rolf Fimmers; Clemens Kratochwil; Hendrik Rathke; Harun Ilhan; Johanna Maffey-Steffan; Mike Sathekge; Levent Kabasakal; Francisco Osvaldo Garcia-Perez; Kalevi Kairemo; Masha Maharaj; Diana Paez; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-08       Impact factor: 9.236

7.  The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.

Authors:  Masha Maharaj; Lucille Heslop; Trisha Govender; Nisaar Korowlay; Aviral Singh; Partha Choudhary; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2021-04-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.